Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared Weiss

Showing results (41-50 of 95) with videos related to

Pageof 10
Sort By:
Clinical Lung Cancer|April 11, 2018
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung CancerJuneko E Grilley-Olson, Jared Weiss, Anastasia Ivanova, et al.
Oral Oncology|August 18, 2018
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neckJared Weiss, Jill Gilbert, Allison Mary Deal, et al.
The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
Nature Communications|April 21, 2022
Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migrationHongxia Li, Emily B Harrison, Huizhong Li, et al.
Oral Oncology|August 22, 2020
Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck - Mature clinical and functional outcomesTrevor G Hackman, Samip N Patel, Allison M Deal, et al.
Frontiers in Oncology|February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled AnalysisCorey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
The Lancet. Oncology|September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trialVivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Oral Oncology|March 9, 2022
Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinomaSiddharth Sheth, Jill Gilbert, Allison Mary Deal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice GuidelineShlomo A Koyfman, Nofisat Ismaila, Doug Crook, et al.
Cancer Treatment and Research Communications|March 11, 2019
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinibJared Weiss, Brian Kavanagh, Allison Deal, et al.
Pageof 10

Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
Clinical Lung Cancer|April 11, 2018
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung CancerJuneko E Grilley-Olson, Jared Weiss, Anastasia Ivanova, et al.
Oral Oncology|August 18, 2018
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neckJared Weiss, Jill Gilbert, Allison Mary Deal, et al.
The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
Nature Communications|April 21, 2022
Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migrationHongxia Li, Emily B Harrison, Huizhong Li, et al.
Oral Oncology|August 22, 2020
Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck - Mature clinical and functional outcomesTrevor G Hackman, Samip N Patel, Allison M Deal, et al.
Frontiers in Oncology|February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled AnalysisCorey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
The Lancet. Oncology|September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trialVivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Oral Oncology|March 9, 2022
Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinomaSiddharth Sheth, Jill Gilbert, Allison Mary Deal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice GuidelineShlomo A Koyfman, Nofisat Ismaila, Doug Crook, et al.
Cancer Treatment and Research Communications|March 11, 2019
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinibJared Weiss, Brian Kavanagh, Allison Deal, et al.
Pageof 10